



ASX ANNOUNCEMENT

3 JULY 2018

**Senior Executive Changes and New Appointments
including Former Masimo and Johnson & Johnson Executives**

- **New appointments to support CardieX's repositioning as a global health tech provider & ongoing restructure to focus on growth opportunities;**
- **Recruitment of former Masimo, Inc (NASDAQ:MASI US\$5B) executive ZiHan Lin to head of CardieX's Asian strategy with a focus on the Chinese market and new wearable device technologies;**
- **Appointment of former Johnson & Johnson executive Rhonda Welch to drive new strategic initiatives and reimbursement strategies;**
- **Doug Kurschinski promoted to Executive VP & Head of Global Sales of AtCor Medical division;**
- **Former CEO, Duncan Ross leaves the company effective 1 July 2018.**

CardieX Limited (ASX: CDX, CardieX, the Company) is pleased to announce the following key changes to its executive team and appointments:

Former Masimo, Inc (NASDAQ:MASI US\$5B) Executive Joins as Director of Corporate Development

Mr ZiHan Lin has been appointed Director of Corporate Development of CardieX. Mr Lin was formerly the Director of North Asia for Masimo, Inc, the US\$5B market cap (NASDAQ:MASI) listed medical device company where he focused on the Chinese and Asian strategy for Masimo's portfolio of devices.

Masimo sells more pulse oximetry devices (a non-invasive method for monitoring a person's oxygen saturation) to hospitals than any other Company globally and has been recognised both for its intellectual property and for being one of the most innovative companies in the medical device industry.

Mr Lin will be focusing on expanding the opportunity for CardieX's products in the Chinese market as well as accelerating the commercialization of CardieX's cardiovascular technologies into new devices and technologies. Mr Lin is based in Orange County, California, the hub of California's medical technology industry, and will report directly to the CEO.

Former Johnson & Johnson Executive Joins Company Advisory Board

Ms Rhona Welch also joins CardieX as a member of the Company's Advisory Board which will expand with appropriate and experienced industry executives to lend support to the Board and Management. Ms Welch will be working closely with the Company's executive team in the development of new opportunities and business strategy with respect to the expansion of CardieX's technologies and reimbursement programs.

Ms Welch is a 20-year veteran of the US healthcare industry and was a former Director of Health Policy Reimbursement at Johnson & Johnson. Her expertise includes new medical device reimbursement assessment and strategy, development of value propositions targeted to payers and health administration, integration of economic value into the product development process, and field training in the changing healthcare environment.

New Local US Leadership and Appointment

Mr Doug Kurschinski has been promoted to Executive Vice President and Head of Global Sales of CardieX's AtCor Medical division. Mr. Kurschinski was previously Senior Vice President and General Manager of AtCor Medical where he led the US sales team.

Mr Kurschinski will head the AtCor cardiovascular division as well as the global sales team supporting that operation. Commensurate with Mr Kurschinski's new role, former Company CEO Duncan Ross has left the company effective 1 July 2018.

CardieX CEO, Craig Cooper said: "I'm extremely excited about the new team we are assembling at CardieX as we position the Company for long-term growth and expansion into new markets. I previously announced a major strategic repositioning for the Company in March of this year and these initial new appointments and executive team changes are a key step towards that goal".

For more information please contact:

Chief Executive Officer
Craig Cooper
Ph: +61 429 993 399
c.cooper@atcormedical.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231
peter@nwrcommunications.com.au

About CardieX

CardieX is a global health technology company focused on developing solutions for large-scale population health disorders. The Company's "AtCor Medical" division develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease.